Patient-specific stem cell lines derived from human parthenogenetic blastocysts

a technology of parthenogenetic blastocysts and stem cells, applied in the field of embryonic stem cells, can solve problems such as teratoma formation, and achieve the effect of minimizing the use of animal-derived cells and high levels of alkaline phosphatase and telomerase activity
US20080299091A1Inactive Publication Date: 2008-12-04INT STEM CELL CORP
3 Cites 41 Cited by

Patent Information

Authority / Receiving Office
US Β· United States
Patent Type
Applications(United States)
Current Assignee / Owner
INT STEM CELL CORP
Publication Date
2008-12-04
Estimated Expiration
Not applicable Β· inactive patent

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

Methods are disclosed for generating HLA homozygous parthenogenetic human stem cell (hpSC-Hhom) lines from both HLA homozygous and HLA heterozygous donors. These hpSC-Hhom lines demonstrate typical human embryonic stem cell morphology, expressing appropriate stem cell markers and possessing high levels of alkaline phosphatase and telomerase activity. Additionally, injection of these cell lines into immunodeficient animals leads to teratoma formation. Furthermore, in the case of HLA heterozygous donors, the hpSC-Hhom lines inherit the haplotype from only one of the donor's parents. SNP data analysis suggests that hpSC-Hhom lines derived from HLA heterozygous oocyte donors are homozygous throughout the genome as assessed by single-nucleotide polymorphism (SNP) analysis. The protocol as disclosed minimizes the use of animal-derived components, which makes the stem cells more practical for clinical application.
Need to check novelty before this filing date? Find Prior Art

Description

RELATED APPLICATIONS

[0001] This application claims benefit of U.S. Provisional Application No. 60 / 922,244, filed Apr. 6, 2007, which is herein incorporated by reference in its entirety.BACKGROUND OF THE INVENTION

[0002] 1. Field of the Invention

[0003] The present invention relates generally to embryonic stems cells, and more specifically to a process for obtaining HLA homozygous parthenogenetic human stem cell lines for cell-based therapy.

[0004] 2. Background Information

[0005] The first human embryonic stem cells (ESC) were derived from a blastocyst inner cell mass (ICM) obtained from a fertilized oocyte, capable of infinite division and differentiation into cells of all tissues types. The embryonic stem cell is a potentially limitless source of pluripotent cells for transplant-based cell therapies.

[0006] Human embryonic stem cells (ES) cells are pluripotent cells that can differentiate into a large array of cell types. When injected into immune-deficient mice, embryonic stem cells form di...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More